FCFelix Chua

Felix Chua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Felix Chua has a total of 325 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • BAL cells analysis and lung function parameters in fibrotic hypersensitivity pneumonitis at baseline and in relation to survival

    by Punchalee Kaenmuang, Fiammetta Danzo, Simon Bax, Richard J. Hewitt, Maria Kokosi, Vasileios Kouranos, Felix Chua, Peter M. George, Gisli Jenkins, Athol U. Wells, et al.

  • Open Access

    Pharmaco-economic Inequalities in Access to Antifibrotic Treatment for Interstitial Lung Disease in the Asia-Pacific Region

    by Felix Chua, Larry Ellee Nyanti, Shirin Hui Tan, Syazatul Syakirin Sirol Aflah, Sze Shyang Kho, Gin Tsen Chai, Amornpun Wangkarnjana, Su-Ying Low, Sita Andarini, Lutz Beckert, et al.

    Antifibrotic drugs, available for the best part of the last decade in many parts of the world, have improved outcomes in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. However, it is unclear whether patients suffering from these devastating conditions have timely and adequate access to antifibrotic therapy in the Asia-Pacific region (APAC). In this mixed-methods narrative review of 12 APAC countries, integration of questionnaire-based insights of 31 regional clinical experts in interstitial lung disease (ILD) with publicly available pharmaco-economic information has been used to understand how country-specific challenges impact on antifibrotic accessibility. Overall, a broad range of approaches are utilized to provide antifibrotic treatment including centrally or state-determined drug budgets, pharmaceutical industry- subsidized initiatives, charitable support and self-paying (out-of-pocket) options. Impediments to antifibrotic access commonly arise from prohibitive drug pricing in relation to income, absence of universal coverage for pharmaceutical costs, lack of formal pharmaco-economic analysis or restrictions on the use of generic preparations. Unequal access to antifibrotic drugs is a vital unmet therapeutic need in the APAC region, one that is likely to be exacerbated by a rising fibrotic ILD burden.


  • Associations of interstitial lung disease subtype and CT pattern with lung function and survival

    by John S Kim, Janelle Pugashetti, Shwu-Fan Ma, Yong Huang, Anna J Podolanczuk, David A Lynch, Andrea Oh, Josyf Mychaleckyj, Ani Manichaikul, Stephen Rich, et al.

    Background Prior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, epidemiological data with longitudinal sampling and replication remains lacking. Methods Data was used from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR) (n=932) and a meta-cohort of ILD research studies (n=1579). Linear mixed-effects models and Cox proportional hazard models were used to determine forced vital capacity (FVC) slopes and 5-year transplant-free survival, respectively, by ILD diagnosis and UIP radiological pattern. Secondarily, we examined FVC and survival by diagnosis and radiological fibrosis quantified by data-driven texture analysis (DTA) in the PFF-PR. Models were adjusted for age, sex, smoking and antifibrotic and immunosuppression medication use. Results The proportions of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP) and connective tissue disease (CTD)-ILD were the following for PFF-PR (70%, 11%, 19%) and meta-cohort (21%, 32%, 47%). In the PFF-PR, CTD-ILD with UIP CT pattern was associated with slower FVC decline (−34.4 mL/year) compared with IPF (−158.4 mL/year) and longer transplant-free survival (HR 0.50, 95% CI 0.29 to 0.85). This was replicated in the meta cohort for FVC (−53.1 vs −185.9 mL/year, pConclusions Even in the presence of a UIP CT pattern, there may still be differences in lung function over time and survival, particularly for CTD-ILD.


  • An unusual pulmonary complication of smoking

    by Felix Chua, Josien van Es, Rainer Doffinger, Tom Pickworth, Bart Koopman, Bekir Karakaya, Marcel Veltkamp, Maria Kokosi

  • Open Access

    Artificial stone silicosis: a UK case series

    by Johanna Feary, Anand Devaraj, Matthew Burton, Felix Chua, Robina K Coker, Arnab Datta, Richard J Hewitt, Maria Kokosi, Vaslis Kouranos, Carl Jonathan Reynolds, et al.

    Silicosis due to artificial stone (AS) has emerged over the last decade as an increasing global issue. We report the first eight UK cases. All were men; median age was 34 years (range 27–56) and median stone dust exposure was 12.5 years (range 4–40) but in 4 cases was 4–8 years. One is deceased; two were referred for lung transplant assessment. All cases were dry cutting and polishing AS worktops with inadequate safety measures. Clinical features of silicosis can closely mimic sarcoidosis. UK cases are likely to increase, with urgent action needed to identify cases and enforce regulations.


  • Open Access

    The impact of hiatus hernia in hypersensitivity pneumonitis

    by David A. Heriot, Carmel J. W. Stock, Zain‐Ul‐Abideen Mumtaz, R. Gisli Jenkins, Felix Chua, Phillip L. Molyneaux, Anand Devaraj, Vasilis Kouranos, Athol U. Wells, Elizabetta A. Renzoni, et al.


  • Open Access

    Serum C‐reactive protein is associated with earlier mortality across different interstitial lung diseases

    by Carmel J. W. Stock, William G. Bray, Vasilis Kouranos, Joseph Jacob, Maria Kokosi, Peter M. George, Felix Chua, Athol U. Wells, Piersante Sestini, Elisabetta A. Renzoni

    Background and Objective: The acute‐phase protein C‐reactive protein (CRP) is known to be associated with poor outcomes in cancer and cardiovascular disease, but there is limited evidence of its prognostic implications in interstitial lung diseases (ILDs). We therefore set out to test whether baseline serum CRP levels are associated with mortality in four different ILDs.Methods: In this retrospective study, clinically measured CRP levels, as well as baseline demographics and lung function measures, were collected for ILD patients first presenting to the Royal Brompton Hospital between January 2010 and December 2019. Cox regression analysis was used to determine the relationship with 5‐year mortality.Results: Patients included in the study were: idiopathic pulmonary fibrosis (IPF) n = 422, fibrotic hypersensitivity pneumonitis (fHP) n = 233, rheumatoid arthritis associated ILD (RA‐ILD) n = 111 and Systemic Sclerosis associated ILD (SSc‐ILD) n = 86. Patients with a recent history of infection were excluded. Higher CRP levels were associated with shorter 5‐year survival in all four disease groups on both univariable analyses, and after adjusting for age, gender, smoking history, immunosuppressive therapy and baseline disease severity (IPF: HR (95% CI): 1.3 (1.1–1.5), p = 0.003, fHP: 1.5 (1.2–1.9), p = 0.001, RA‐ILD: 1.4 (1.1–1.84), p = 0.01 and SSc‐ILD: 2.7 (1.6–4.5), p < 0.001).Conclusion: Higher CRP levels are independently associated with reduced 5‐year survival in IPF, fHP, RA‐ILD and SSc‐ILD.


  • Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?

    by Felix Chua, Suying Low, Gin Tsen Chai, Yoshikazu Inoue, Voon Ong, Amornpun Wongkarnjana, Kamon Kawkitinarong, Jin Woo Song, Zuhanis Abdul Hamid, Aida Abdul Aziz, et al.


  • Open Access

    Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study

    by Timothy J. W. Dawes, Colm McCabe, Konstantinos Dimopoulos, Iain Stewart, Simon Bax, Carl Harries, Chinthaka B. Samaranayake, Aleksander Kempny, Philip L. Molyneaux, Samuel Seitler, et al.

    Background and Objective: Pulmonary hypertension is a life‐limiting complication of interstitial lung disease (ILD‐PH). We investigated whether treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with ILD‐PH was associated with improved survival.Methods: Consecutive incident patients with ILD‐PH and right heart catheterisation, echocardiography and spirometry data were followed from diagnosis to death, transplantation or censoring with all follow‐up and survival data modelled by Bayesian methods.Results: The diagnoses in 128 patients were idiopathic pulmonary fibrosis (n = 74, 58%), hypersensitivity pneumonitis (n = 17, 13%), non‐specific interstitial pneumonia (n = 12, 9%), undifferentiated ILD (n = 8, 6%) and other lung diseases (n = 17, 13%). Final outcomes were death (n = 106, 83%), transplantation (n = 9, 7%) and censoring (n = 13, 10%). Patients treated with PDE5i (n = 50, 39%) had higher mean pulmonary artery pressure (median 38 mm Hg [interquartile range, IQR: 34, 43] vs. 35 mm Hg [IQR: 31, 38], p = 0.07) and percentage predicted forced vital capacity (FVC; median 57% [IQR: 51, 73] vs. 52% [IQR: 45, 66], p=0.08) though differences did not reach significance. Patients treated with PDE5i survived longer than untreated patients (median 2.18 years [95% CI: 1.43, 3.04] vs. 0.94 years [0.69, 1.51], p = 0.003) independent of all other prognostic markers by Bayesian joint‐modelling (HR 0.39, 95% CI: 0.23, 0.59, p < 0.001) and propensity‐matched analyses (HR 0.38, 95% CI: 0.22, 0.58, p < 0.001). Survival difference with treatment was significantly larger if right ventricular function was normal, rather than abnormal, at presentation (+2.55 years, 95% CI: −0.03, +3.97 vs. +0.98 years, 95% CI: +0.47, +2.00, p = 0.04).Conclusion: PDE5i treatment in ILD‐PH should be investigated by a prospective randomized trial.


  • Lung cancer screening provides an opportunity for early diagnosis and treatment of interstitial lung disease

    by Richard J Hewitt, Emily C Bartlett, Rea Ganatra, Haroun Butt, Vasilis Kouranos, Felix Chua, Maria Kokosi, Philip L Molyneaux, Sujal R Desai, Athol U Wells, et al.

    Interstitial lung abnormalities (ILA) can be incidentally detected in patients undergoing low-dose CT screening for lung cancer. In this retrospective study, we explore the downstream impact of ILA detection on interstitial lung disease (ILD) diagnosis and treatment. Using a targeted approach in a lung cancer screening programme, the rate of de novo ILD diagnosis was 1.5%. The extent of abnormality on CT and severity of lung function impairment, but not symptoms were the most important factors in differentiating ILA from ILD. Disease modifying therapies were commenced in 39% of ILD cases, the majority being antifibrotic therapy for idiopathic pulmonary fibrosis.